Back to discover
Disease

Peanut Hypersensitivity

Active therapeutic pipelineEmerging research
1
Publications
8
Clinical trials
2018
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

AR101 Oral Immunotherapy for Peanut Allergy.

Research2018-11-18The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2027.

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

AR101 Oral Immunotherapy for Peanut Allergy.

The New England journal of medicine · 2018 · 524 cites
Recent publications

AR101 Oral Immunotherapy for Peanut Allergy.

The New England journal of medicine · 2018 · 524 cites
Leading journals1
  • The New England journal of medicine1
Leading researchers8
  • Adelman DC1
  • Anagnostou A1
  • Assa’ad AH1
  • Ben-Shoshan M1
  • Beyer K1
  • Bindslev-Jensen C1
  • Bird JA1
  • Blumchen K1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Allergic reaction to peanuts that is triggered by the immune system.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.